← Leaderboards
John Isaacs
Johns Hopkins University
$1,485,085
Attributed
$1,485,085
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $269.5K · FY2008–13$500K$375K$250K$125K$0
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$1,485,085 · 1
By mechanism
P50$1,485,085 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Kenneth J. Pienta$43,861,680
- Martin G Pomper$38,517,075
- William George Nelson$34,555,726
- Deborah J Anderson$20,708,269
- Dan Stoianovici$4,135,302
Others in their field
Top investigators on “Paper”
- Jeffrey P Krischer · University Of South Florida$403,708,559
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$86,500,967
- Patrick J McCarthy · Carnegie Institution Of Washington$86,500,967
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$82,226,988
- Mark R Farfel · Hugo W. Moser Res Inst Kennedy Krieger$80,506,780
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$77,827,956
Research focus
PaperPrincipal InvestigatorInhibitor/AntagonistNormal Tissue MorphologyPeptide HydrolasesPreventionEvaluationHuman MaleLocal TherapyNamesEpithelial CellsCellsCessation Of LifeChemotherapeutic AgentChymotrypsinAndrogen ReceptorAmericanHormone Refractory Prostate CancerAndrogensDisseminated Malignant NeoplasmDocetaxelMalignant Neoplasm Of ProstateAblationPrograms
Grant awards (6)
Evaluation of the Role of PSA Inhibitors in the Prevention and/or Therapy of$163,358
P50 · FY2013 · CA · contact PI
Evaluation of the Role of PSA Inhibitors in the Prevention and/or Therapy of$269,523
P50 · FY2012 · CA · contact PI
Evaluation of the Role of PSA Inhibitors in the Prevention and/or Therapy of$256,538
P50 · FY2011 · CA · contact PI
Evaluation of the Role of PSA Inhibitors in the Prevention and/or Therapy of$266,121
P50 · FY2010 · CA · contact PI
Evaluation of the Role of PSA Inhibitors in the Prevention and/or Therapy of$264,871
P50 · FY2009 · CA · contact PI
Evaluation of the Role of PSA Inhibitors in the Prevention and/or Therapy of$264,674
P50 · FY2008 · CA · contact PI